Barbara Maria Frigieri

Barbara Maria Frigieri

Auto-generated profile, based on publicly available information

Barbara Maria Frigieri

Cancer Molecular Research Laboratory (CMRL), Faculdade de Medicina de São José do Rio Preto—FAMERP São José do Rio Preto Brazil

Research Focus & Metrics

Academic Career Length

1Year (2026-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 August 2026 in Journal of Cellular and Molecular Medicine
Verified
Journal Article
Open access
BFBarbara Maria Frigieri
Barbara Maria Frigieri
GBGuilherme Silva Bruno Barbosa
Guilherme Silva Bruno Barbosa
ANAdriana Alonso Novais
Adriana Alonso Novais
CRCaroline Rezende
Caroline Rezende
Fausto AlmeidaFausto Almeida
Fausto Almeida
Debora Aparecida Pires Campos ZuccariDebora Aparecida Pires Campos Zuccari
Debora Aparecida Pires Campos Zuccari
Extracellular vesicles (EVs/EV) are key mediators of intercellular communication and influence proliferation, migration, and metabolic reprogramming. In breast cancer, EVs released by malignant cells carry bioactive molecules capable of altering the behaviour of surrounding cells. However, it remains uncertain whether these vesicles can directly induce a more aggressive phenotype in benign mammary cells. Melatonin, known for its oncostatic properties, regulates proliferation, metabolism, and signalling pathways associated with tumour progression and may modulate EV‐mediated intercellular communication. This study evaluated whether EVs derived from four breast cancer cell lines (MCF‐7, MDA‐MB‐231, MDA‐MB‐453 and HCC70), treated or not with melatonin, can modify the phenotype of benign MCF10A cells. EVs were isolated from conditioned media and co‐cultured with benign cells. Assays of proliferation, viability, colony formation, migration, lactate production and immunofluorescence were performed to assess EV‐mediated effects. EVs derived from malignant cells promoted a more aggressive phenotype in benign cells, as evidenced by increased proliferation, migration, and phenotypic remodelling. In contrast, EVs derived from melatonin‐treated malignant cells were associated with reduced lactate production and attenuation of pro‐tumoural features. Overall, these findings demonstrate that tumour‐derived EVs can induce aggressive traits in benign mammary cells and suggest that melatonin exposure in donor cells modulates EV‐mediated effects, attenuating their pro‐tumoural influence.